Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Denali Therapeutics Inc.
Age
30–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body mass index (BMI) between 18 and 35.0 kg/m2, inclusive
Clinical diagnosis of Parkinson's disease meeting UK Brain Bank criteria and H\&Y Stage I, II, or III.
sPD subgroup without a LRRK2 mutation; PD LRRK2 subgroup with LRRK2 mutation
Screening dopamine transporter (DAT) SPECT scan with a DAT deficit consistent with Parkinson's disease
Able to hold Parkinson's disease medications 8 hours (overnight) prior to specific study assessments
You may not be if
Any history of clinically significant asthma, chronic obstructive pulmonary disease, or emphysema within 5 years of screening, or other clinically significant pulmonary disease within 6 months of screening
Abnormal Vitals including Respiratory Rate, Body Temperature, and Blood Pressure
Pulmonary Function Tests (PFTs) (FVC \<60% predicted, FEV1 \<50% predicted, FEV1:FVC ratio \<0.6, DLCO \<70% predicted)
Clinically significant neurologic disorder other than Parkinson's disease, including history of stroke, cognitive impairment, seizure within 5 years of screening, or head trauma with loss of consciousness within 6 months of screening
Montreal Cognitive Assessment (MoCA) score of \<24 at screening
Clareo Health | Study to Evaluate DNL201 in Subjects With Parkinson's Disease
